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doi:10.1016/j.jalz.201forego needed services and medications as well as hamper their ability to pay for other essential
goods. Because it leads to disability and the loss of independence, dementia may put patients and their
families at risk for high OOP spending, especially for long-term care services.
Methods: We used data from the Aging, Demographics, and Memory Study, a nationally represen-
tative subsample (n 5 743) of the Health and Retirement Study, to determine whether individuals
with dementia had higher self-reported OOP spending compared with those with cognitive impair-
ment without dementia and those with normal cognitive function. We also examined the relationship
between dementia and utilization of dental care and prescription medications—two types of health
care that are frequently paid for OOP. Multivariate and logistic regression models were used to adjust
for the influence of potential confounders.
Results: After controlling for demographics and comorbidities, those with dementia had more than
three times the yearly OOP spending compared with those with normal cognition ($8216 for those
with dementia vs. $2570 for those with normal cognition, P , .01). Higher OOP spending for those
with dementia was mainly driven by greater expenditures on nursing home care (P, .01). Dementia
was not associated with the likelihood of visiting the dentist (P 5 .76) or foregoing prescription
medications owing to cost (P 5 .34).
Conclusions: Dementia is associated with high levels of OOP spending but not with the use of dental
care or foregoing prescription medications, suggesting that excess OOP spending among those with
dementia does not “crowd out” spending on these other health care services.
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The Medicare health insurance program offers nearly
universal coverage for Americans aged 65 years and older,
but paying for deductibles, copayments, and uncovered
services may, nonetheless, represent a substantial financial
burden. High levels of out-of-pocket (OOP) spending for
health care are potentially problematic because they may
lead patients to forego needed services and medications as
well as hamper their ability to pay for other essential goods,
such as food and housing, leading to sharp reductions inthor. Tel.: 310-393-0411; Fax: 310-260-8011.
co@rand.org
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1.11.003quality of life [1–4]. High OOP spending among those
with illness and injury has also been cited as a common
cause for personal bankruptcy [5] The significance of this
issue is underscored by recent trends toward increasing
OOP health care spending; 1 in 10Medicare recipients spend
at least 60% of their income on health care costs, up from
48% in 1997 [6]. Concerns about OOP spending have risen
to prominence in the national policy discussion. Medicare
Part D was enacted in 2006 mainly to protect seniors from
high OOP spending on prescription drugs [7]. There are
also calls to extend Medicare coverage to long-term care,
another current source of high OOP expenditures [8].
Dementia is a chronic condition of aging characterized by
cognitive decline that leads to a loss of independence. Owingeserved.
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rates of dementia and population projections suggest that
by 2040 the number of dementia cases will nearly triple
(from approximately 3.4 million to 9.5 million cases).
Because dementia limits the ability to function indepen-
dently, demented individuals are much more likely to use
long-term care facilities, such as nursing homes [9–11].
Medicare and private insurance coverage for these services
are limited, and therefore, spending on long-term care repre-
sents the largest share of OOP expenditures for Medicare
recipients [12]. Medicaid, the federal-state insurance
program, does provide coverage for long-term care, but
patients typically must meet income and asset tests to be
eligible for Medicaid (eligibility rules vary across states).
Consequently, patients suffering from dementia are at high
risk of incurring very large OOP expenditures until they
have “spent down” their assets below the Medicaid eligibil-
ity threshold [13–15].
Although there are reasons to suspect that dementia
leads to higher levels of spending and health care utilization,
the evidence remains mixed. Some studies find higher levels
of cost and utilization among demented individuals [16–19],
whereas others find reductions [20,21]. A key limitation of
this line of research is the lack of data with reliable
information on both costs and dementia diagnoses. Studies
[17] using claims records have high-quality data on costs
incurred by the payer, but they severely understate the
prevalence of dementia and have limited information on
spending on uncovered services (such as long-term care)
[11,22–24]. Other studies use self-reported levels of OOP
spending available in nationally representative data such as
the Health and Retirement Study (HRS), but until recently,
these data had no information on actual diagnoses of demen-
tia [19,21]. In addition, owing to the sampling frame of the
HRS, the samples used in earlier analyses likely
undersampled individuals residing in nursing homes, who
are precisely those at the greatest risk for very large OOP
expenses [19]. Finally, no studies we are aware of have
directly examined whether dementia reduces spending on
types of medical care that are not directly related to dementia
and that are typically paid for OOP. Were that to be the case,
a possible explanation would be that high spending for
dementia reduces economic resources for other types of
health care spending, which could have additional health
impacts.
This article addresses these limitations using newly avail-
able data from the Aging, Demographics, and Memory
Study (ADAMS), a substudy of the HRS. The ADAMS in-
cludes clinical diagnoses of dementia status for a sample
of individuals drawn from the HRS. We estimate the rela-
tionship between dementia and OOP spending for health
care as well as between dementia and two types of health
care that are typically paid for OOP and are not associated
with dementia. Specifically, we use these data to test the
following three hypotheses:1. Dementia is associated with higher average OOP
spending.
2. The increase in average OOP spending is driven by
the incidence of large OOP expenditures on long-
term care services, which are heavily used by individ-
uals with dementia but are not typically covered by
insurance.
3. Dementia reduces utilization of two types of health
care (dental care and prescription drugs) that are not
directly associated with care for dementia and that
are typically paid for OOP.
This study is the first of its kind to use nationally repre-
sentative data that combine information on (1) clinical diag-
noses of dementia, (2) information on health care utilization
and expenditures, and (3) detailed information on demo-
graphic characteristics and comorbidities that may confound
the relationship between dementia and OOP spending. It is
also the first study that we are aware of that uses nationally
representative data to explicitly address whether dementia
reduces utilization of two types of health care that are
usually paid for OOP.2. Data
2.1. HRS and ADAMS
This study examines the relationship between OOP
spending reported in the HRS and diagnoses of dementia
status made among individuals in the ADAMS. The HRS
is a nationally representative longitudinal survey of individ-
uals aged 51 years and older that began in 1992. Since 1996,
the HRS core interviews have been conducted every 2 years.
All individuals who enter the HRS are recruited from the
community, but the HRS follows subjects even if they enter
facilities such as nursing homes. The core interviews collect
information on a wide variety of topics, including health
status, health care utilization and spending, wealth and
income, and employment histories [25]. All spouses of
HRS respondents are interviewed, regardless of year of birth.
Proxy interviews are used for study subjects who are unable
to complete the survey interview without assistance.
HRS respondents aged 70 years and older formed the
basis for the ADAMS sampling frame, the first nationally
representative study of dementia in the United States. Sub-
jects in ADAMS were drawn from either the 2000 or 2002
HRS. Sampling was stratified based on age, gender, and cog-
nitive functioning, as measured by the cognitive assessment
administered to HRS respondents. The final ADAMS sample
consists of 856 respondents of 1770 who were recruited,
which gives a response rate of 56%, net of mortality [26].
We further limit the sample to the 743 individuals who
completed the HRS interview after the ADAMS assessment
because, as explained later, this was when information on
health care expenditures made during the period of the
ADAMS assessment was collected.
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includes a more representative sample of individuals living
in nursing homes than was available in earlier studies.
Because the HRS initially interviews only those individuals
residing in the community, early waves of the HRS con-
tained relatively few nursing home residents. Consequently,
the relationship between health care utilization and dementia
may have been understated in earlier research that used data
from the 1995 wave of the HRS [19,21]. In contrast, the
ADAMS has more complete data on individuals residing
in nursing homes, the population most at risk for large
OOP expenditures owing to dementia.2.2. Dementia status
Subjects recruited to be in the ADAMS and who agreed to
participate in the study received an in-home clinical assess-
ment of dementia status between the core HRS waves. The
procedures underlying the diagnosis are described in detail
in the article by Langa et al [27]. Briefly, these diagnoses
were based on data collected during a 3- to 4-hour evaluation
conducted approximately 1 year after the most recent HRS
interview. Information was collected from a knowledgeable
informant, from the respondent, and from medical records.
A panel of experts (psychologists, psychiatrists, neurolo-
gists, and internists) then reviewed this information and
assigned diagnoses, which fell within three general cate-
gories—“normal,” “cognitive impairment, not demented”
(CIND), or “demented.” In our analysis sample, 11.4% of
the subjects were diagnosed as demented, 21.4% as CIND,
and 67.2% as normal, where these are weighted averages
to account for the stratified sampling in ADAMS.Fig. 1. Reference period for the questions on out-of-pocket spending and
the timing of the Aging, Demographics, and Memory Study diagnoses.2.3. OOP spending and health care utilization measures
In the core interview, HRS respondents (or proxy respon-
dents) are asked about their utilization and health care cov-
erage, and then whether they incurred any OOP expenses.
Starting with the 2002 wave, the HRS asked about spending
on the following services: (1) nursing home stays, (2) hospi-
tal stays, (3) doctor visits, (4) dental visits, (5) outpatient sur-
gery, (6) home health care, (7) other “special” services, (8)
prescription drugs, and (9) dental services. Our analyses
examine annual spending. For all spending aside from that
on prescription drugs, the questions refer to total OOP
spending incurred over the past 2 years, which we convert
to annual values by dividing the reported amounts by 2.
The questions about spending on prescription drugs ask
about average monthly OOP spending over the past 2 years,
which is converted to an annual total by multiplying by 12.
All values are converted to 2010 dollars using the medical
care consumer price index.
We analyze total annual OOP spending as well as OOP
spending by health care type. Specifically, we separate
OOP expenditures into those for nursing home stays, spend-
ing on prescription drugs, and spending on all other types ofmedical care. Total spending is partitioned in this way for
two reasons. First, public and private insurance coverage
for nursing home care and prescription drugs is typically
much less generous than it is for other types of care. Second,
existing evidence suggests that dementia increases the
likelihood of nursing home stays [9].
Because long nursing home stays owing to dementia
could result in extremely large OOP spending costs, the
second type of outcome we use is an indicator variable for
the incidence of very high annual OOP spending, which is
defined as spending greater than $5000 per year (roughly
the 85th percentile of the OOP spending distribution, and
23% of median income in the sample). Other cutoff values
were explored as sensitivity analyses, which are discussed
later in the text.
A key issue in this study is the quality of the self-reported
information on OOP spending, which, as previous research
suggests, is often understated [28,29]. However,
underreporting is mitigated in the HRS questionnaire in
two ways. First, separate questions are asked about
spending on various services, which helps respondents
recall incidents that may be forgotten with a single “catch-
all” question [29]. Second, questions are asked using an
“unfolding bracketing” method. Respondents who are
unable or unwilling to provide an exact figure are presented
with a series of questions such as “Was it more (or less) than
$2000?”. Based on the responses to these questions, an exact
dollar figure is imputed [30]. The bracketing procedure has
been shown to reduce underreporting of economic concepts
such as OOP spending [31]. Another indication of the valid-
ity of the HRS OOP spending information is that OOP
spending increases with utilization of health care (within
insurance coverage categories), suggesting that the HRS
spending data are internally consistent [32].
A second issue concerns which HRS wave should be used
for information on OOP spending. We use the HRS inter-
view after ADAMS because it has the most relevant informa-
tion on spending and utilization occurring during the
assessment. This is because the ADAMS was conducted in
the middle of the reference period for the OOP spending
questions from the HRS interview after ADAMS. This can
be seen in the study diagram depicted in Figure 1, which
shows the reference period for the HRS questions on OOP
spending and the approximate timing of the ADAMS diag-
noses. The drawback of this approach is that ADAMS
subjects who did not complete the subsequent HRS
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section, we describe the potential implications of excluding
these individuals and discuss the results of a sensitivity
analysis where we use information drawn from the HRS
interview used to select individuals into ADAMS.
2.4. Utilization of other types of care
To investigate the hypothesis that dementia reduces
spending on two types of health care services, which are
usually only partially covered by insurance, we examine
the association between dementia and the use of prescription
medications and dental care. Both of them receive much less
generous coverage by Medicare (at least before Medicare
Part D, which was adopted after the study period) than other
services. The first outcome we study is a variable indicating
whether respondents had taken less medication than what
was prescribed because of the medication’s cost. This mea-
sure is especially useful for our purposes because it relates
specifically to foregone care due to an inability to pay, and
it has been used in other studies examining whether patients
underutilize medications owing to cost [33,34]. The second
measure is whether the HRS respondent had visited the
dentist in the past 2 years. This outcome is somewhat less
useful because individuals with dementia might be unable
to visit the dentist because of their cognitive impairment
[21] rather than because they cannot pay for it.
2.5. Controls for comorbidities and demographic
confounders
Because dementia may be correlated with other determi-
nants of OOP spending, it is important to adjust for factors
that could confound the relationship between dementia and
OOP spending. Fortunately, the HRS has considerable
information on demographic and health conditions that we
control for in the analysis of OOP spending. In the analysis,
we used the following measures of demographic and
economic status as controls for potential confounders: age
(and age squared), proxy respondent status, marital status,
number of children (dichotomous variables for zero or one
child, two children, and three or more children), race (a di-
chotomous variable for whether the respondent is white),
health insurance status (dichotomous variables for covered
by long-term care insurance, covered by Medicaid, and cov-
ered by supplemental private insurance), gender, education
(dichotomous variables for high school dropout, high school
graduate, and at least some college), and household income.
We also used information on the following comorbidities (all
defined as dichotomous variables): stroke, diabetes, heart
disease, hypertension, lung disease, cancer, psychiatric
problems (which includes depression), and arthritis.3. Methods
Our goal is to estimate the increase in OOP spending
attributable to dementia. The simplest estimates we reportsimply compare the average spending levels by dementia
status. These unadjusted estimates are useful for describing
patterns in the data but may be misleading for understanding
the increase in OOP spending attributable to dementia.
Therefore, our preferred approach is to estimate multivar-
iate models that control for potential confounding factors.
For the OOP spending measures, we estimate ordinary least
squares regression models. Estimates from this type of
model are informative about how average OOP spending
changes with dementia status, conditional on covariates
included in the model. For dichotomous outcomes, we use
logistic regression.
The multivariate models include controls for all the
demographic, economic, and comorbidity measures listed
previously. These variables were chosen because they may
be associated with dementia but may themselves have inde-
pendent effects on OOP spending or health care utilization.
For instance, we control for marital status and the number of
offspring a respondent has because both of these are corre-
lated with dementia status in the data but may affect the
demand for nursing home care, as care by relatives can be
a substitute for institutional care [35]. We did not control
for self-reported health or functional status limitations
because these are likely to be manifestations of dementia,
and therefore, any costs associated with them should be
attributed to dementia.
As noted in section 2.2., the dementia status measure
categorizes individuals into one of three categories—normal
cognitive functioning, CIND, and demented. To handle this
three-level classification scheme, the statistical models
include two dummy variables—the first equal to one if an
individual has dementia and zero otherwise, and the second
equal to one if an individual is CIND and zero otherwise.
Estimates of the average level of OOP spending for each
dementia category are then obtained using predictions
from the ordinary least squares regressions when the covari-
ates (other than the dementia status indicators) are set to the
overall sample mean. Similarly, we compute the incidence
rate for dichotomous outcomes (e.g., foregoing prescription
medication owing to cost) by dementia status level using
predictions from the logistic regression.
Comparing predicted average spending (or the incidence
rate for a dichotomous outcome) between different dementia
levels has the interpretation of the difference in the average
of a given outcome associated with a change from one
dementia status category to another after adjusting for the
covariates and comorbidities listed previously. We report
the P value corresponding to the hypothesis test that adjusted
average spending (or the incidence rate) is the same across
the three dementia levels. We also discuss whether the
incremental change in a given outcome associated with
a change from normal cognitive functioning to CIND is
the same as the change associated with progressing from
CIND to dementia, as this is informative about the trend
in an outcome associated with a decline in cognitive
functioning.
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account for nonproportional sampling and differential
nonresponse. Furthermore, standard errors are computed
using STATA 10’s “survey” commands that adjust for the
complex survey design of ADAMS (StataCorp LP, College
Station, TX).4. Results
4.1. Descriptive statistics
Table 1 shows descriptive statistics of the analysis
sample. Relative to sample members who were diagnosed
as “normal,” those with dementia are 6.3 years older
(P , .01), more likely to be nonwhite (P 5 .02), single
(P , .01), and to have a proxy interview (P , .01). Individ-
uals with dementia also have lower socioeconomic status, as
indicated by the higher incidence of having less than a high
school degree (P , .01) and lower average household
income (P , .01). There are also differences by dementia
status in the likelihood of having certain comorbidities,
such as stroke and heart disease, although other conditions,
such as hypertension, diabetes, lung diseases, and cancer,
show smaller and statistically insignificant differences
across dementia diagnoses. With a few exceptions (such
as the fraction of male subjects), the average of these
characteristics among those with CIND falls in between
the average for individuals diagnosed as normal or having
dementia.Table 1








Have long-term care insurance 0.104
Have supplemental private insurance 0.306
Covered by Medicaid 0.114
Less than high school 0.345
High school graduate 0.271
More than high school 0.384












Number of observations 743
Abbreviations: CIND, cognitive impairment, not demented; HRS, Health and R
NOTE. P value refers to differences in means across dementia status categorie4.2. Unadjusted comparisons by dementia status
Unadjusted OOP spending and health care utilization by
dementia status are reported in Table 2. The results clearly
show that OOP spending is strongly associated with having
dementia. Average OOP spending among those with demen-
tia is $10,039, which is more than four times the average for
individuals diagnosed as normal, and twice the mean for
those classified as CIND (P , .01).
These differences are concentrated in the right tail of the
distribution of OOP spending. The incidence of having
annual spending exceeding $5000 is 28% among those
with dementia compared with only 11% among those diag-
nosed as normal (P , .01). Virtually all of these differences
are driven by higher OOP spending on nursing home care by
those with dementia. Nearly 30% of demented individuals
have some OOP spending on nursing home care compared
with only 1% of those classified as normal (P , .01), and
individuals with dementia spend an average of $7175 per
year on nursing home care compared with $1529 for those
classified as CIND and close to zero for those with normal
cognitive functioning (P , .01). Notably, the increase in
OOP spending on nursing homes associated with a change
from CIND to dementia ($5646) is nearly four times the
increase associated with a change from normal cognitive
functioning to CIND ($1525; P 5 .03), suggesting that the
trend in OOP spending on nursing homes associated with
cognitive decline accelerates as individuals become
demented. In contrast, spending on prescription drugs andDemented CIND Normal P value
0.311 0.456 0.382 .055
0.160 0.392 0.515 ,.001
0.334 0.293 0.212 .040
0.189 0.146 0.225 .140
0.777 0.800 0.889 .017
0.044 0.057 0.049 .709
0.051 0.114 0.110 .179
0.198 0.297 0.327 .020
0.316 0.151 0.068 ,.001
0.540 0.452 0.279 ,.001
0.202 0.286 0.278 .113
0.258 0.263 0.444 ,.001
10.2 10.4 10.3 .976
84.9 81.9 78.6 ,.001
20,166 22,877 39,299 ,.001
0.459 0.214 0.082 ,.001
0.188 0.278 0.191 .157
0.455 0.519 0.288 ,.001
0.613 0.589 0.657 .513
0.111 0.188 0.079 .079
0.146 0.231 0.208 .194
0.353 0.183 0.172 ,.001
0.783 0.777 0.752 .733
0.452 0.134 0.022 ,.001
229 215 299
etirement Study; ADAMS, Aging, Demographics, and Memory Study.
s.
Table 2
Unadjusted annual OOP spending and health care utilization, by dementia status
All (N 5 743) Demented (N 5 229) CIND (N 5 215) Normal (N 5 299)
Mean SE Mean SE Mean SE Mean SE P value
Total annual OOP spending 3705.2 417.4 10,039.2 2336.5 5061.8 520.1 2200.8 216.7 ,.001
Annual OOP spending on nursing home care 1146.9 384.2 7175.1 2259.6 1528.8 962.5 4.3 3.6 .009
Annual OOP spending on prescription drugs 1567.3 159.7 1425.6 193.3 1893.1 406.0 1487.7 165.4 .525
Annual OOP spending on other care 991.0 199.6 1438.5 438.0 1639.9 848.9 708.8 119.0 .518
Annual OOP spending on nursing home care .0 0.057 0.011 0.289 0.057 0.083 0.027 0.010 0.006 ,.001
Annual OOP spending .$5000 0.147 0.019 0.282 0.053 0.185 0.038 0.112 0.018 ,.001
Did not take prescribed medications owing to cost 0.054 0.012 0.036 0.015 0.053 0.022 0.057 0.017 .746
Visited dentist in past 2 years 0.583 0.028 0.367 0.043 0.499 0.056 0.645 0.037 ,.001
Abbreviations: OOP, out of pocket; SE, standard error.
NOTE. P value refers to differences across dementia status categories. Sample size for estimates of the fraction not taking drugs owing to cost is 739, and
sample size for dentist visits in previous 2 years is 740.
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across dementia categories.
Despite much higher OOP spending for health care
among individuals with dementia, the likelihood of not
taking prescribed medication is not significantly related to
dementia status. However, only one-third of individuals
with dementia reported visiting a dentist in the previous 2
years, compared with two-thirds of individuals classified
as normal (P , .01).4.3. Multivariate analyses
Table 3 shows the relationship between dementia status
and OOP spending and health care utilization after con-
trolling for demographic characteristics and comorbidities
(see Tables A1 and A2 for the complete regression output).
The unadjusted differences in OOP spending remain intact
after controlling for potential confounders. In particular,
the adjusted differences in total annual OOP spending in-
dicate significant differences across dementia categories (P
, .01) that are very similar to the unadjusted figures; for
example, the adjusted difference in OOP spending be-
tween those classified as normal and demented is $5646,
which is only somewhat less than the unadjusted differ-
ence of $7838. Furthermore, these differences are drivenTable 3
Adjusted annual OOP spending and health care utilization by dementia status
Demented
Adjusted mean SE
Total annual OOP spending 8216.3 1460.7
Annual OOP spending on nursing home care 5112.3 1385.5
Annual OOP spending on prescription drugs 1995.7 346.3
Annual OOP spending on other care 1108.3 562.9
Annual OOP spending .$5000 0.308 0.38
Visited dentist in past 2 years 0.485 0.39
Did not take prescribed medications owing to cost 0.027 0.46
NOTE. Entries are the predicted average of the outcome variable evaluated for a
model, except for the dementia status indicator variables. Models adjust for proxy
two), race, insurance status (long-term care insurance, Medicaid, supplemental pri
tions (stroke, diabetes, heart disease, hypertension, lung disease, cancer, psychiatric
categories. Sample size for estimates of the fraction not taking drugs owing to coby higher OOP spending on nursing home care among pa-
tients with dementia (P , .01), and by more than a fourfold
increase in the likelihood of reporting OOP spending
greater than $5000 (P , .01). The results also suggest
that the increase in OOP spending associated with cogni-
tive decline accelerates with the onset of dementia. For ex-
ample, after adjusting for covariates, the increase in OOP
spending on nursing home care associated with a change
from normal cognitive functioning to CIND is statistically
insignificant and only $484 (P 5 .41), whereas the in-
crease associated with a change from CIND to dementia
is $2638 (P 5 .04).
Despite the sizable OOP spending burden associated
with dementia, however, there is no evidence that dementia
leads to a reduction in other types of care that are often paid
for OOP. Dementia is not significantly related to the proba-
bility of foregoing prescription medications owing to cost
(P 5 .34). Similarly, the adjusted differences in the use of
dental care are smaller and no longer statistically significant
after controlling for potential confounders (P 5 .76).4.4. Sensitivity analyses
One concern with the way the models are estimated has to
do with the way they control for proxy respondent status. AsCIND Normal
Adjusted mean SE Adjusted mean SE P value
4872.1 531.7 2569.9 281.8 ,.001
1184.4 882.8 463.3 232.6 ,.001
2035.2 446.8 1345.9 145.9 .261
1652.6 787.9 760.7 128.6 .364
4 0.165 0.360 0.073 0.212 ,.001
5 0.582 0.225 0.639 0.145 .373
5 0.016 0.534 0.020 0.366 .761
given dementia category at the overall sample mean for all covariates in the
respondent status, marital status, number of children (one, two, or more than
vate insurance), gender, education, age and age squared, and chronic condi-
problems, and arthritis). P value refers to differences across dementia status
st is 739, and sample size for dentist visits in previous 2 years is 740.
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impairment, controlling for proxy status could lead to under-
stated estimates of the relationship between dementia and
OOP spending. The results obtained when not controlling
for proxy status are consistent with the patterns described
here, although, as expected, the magnitudes of the estimates
are somewhat larger. For instance, the increase in total OOP
spending associated with dementia (relative to normal) is
$7674 without controlling for proxy status compared with
$5646 when adjusting for proxy status.
We also examined the sensitivity of the cutoff used to
identify very large OOP expenditures. The results indicate
that dementia is associated with a significant increase in
the likelihood of incurring large annual OOP expenditures,
where the cutoff used to define “large” ranges from $4000
to $10,000.5. Discussion
This article estimates the magnitude of the OOP spending
burden associated with dementia. The findings indicate that
dementia is associated with higher levels of average OOP
spending and that this association is driven mainly by spend-
ing on nursing home care. In year 2010 prices, our best
estimate is that those with dementia (or their families) spend
OOP $5646 per year more than those who have normal
cognitive functioning. To put this in perspective, according
to tabulations we did using the Consumer Expenditure
Survey, average spending in 2009 by households where the
head of the household was 75 years or older was $21,900.
Because the ADAMS sample is nationally representative
of the population over the age of 70 years, we can estimate
the total OOP spending associated with dementia. To bring
this up to date, we use the total population over the age of
70 years in 2009, which we take from Census estimates to
be 28.1 million [36]. We take dementia prevalence to be
13.9% (as estimated in the full ADAMS sample) and multi-
ply it by the excess of spending associated with dementia
($5646). From these data, we estimate that there is $22.0 bil-
lion of additional OOP spending in 2010 that is associated
with dementia-related care.
Despite the strong relationship between very high levels
of OOP spending and dementia, there is no evidence of
a relationship between dementia and the use of other care
that is typically paid for OOP. Specifically, dementia is not
significantly related to the utilization of dental care or the
likelihood of foregoing prescribed medication owing to
cost. We interpret this lack of a relationship to mean that
OOP spending for dementia does not drive out spending
for these health care services and goods.
The major strengths of this study are twofold. One is that
it is the first to examine the link between dementia and health
care spending using nationally representative data. Second,
it is also the first study that we know of to provide evidence
about whether dementia is associated with a reduction in the
use of two types of medical care that are frequently financed,at least in part, through OOP spending. This contribution is
important because a key concern about high OOP spending
among elderly individuals is that it will reduce the use of
important medications and other forms of care [2,33]. The
findings reported here suggest that even large OOP
spending burdens might not lead to reduced health care
utilization among elderly individuals with dementia.
However, there are several limitations of this analysis that
should be considered when evaluating these findings. First,
this is an observational study and part of the association
between dementia and OOP spending may be due to unob-
served confounds. That said, the fact that the effects on
OOP spending arise almost entirely through an effect on
nursing home care suggests bias from omitted variables
may be small; if the observed relationship was purely due
to worse health generally among those with dementia, then
we would expect to see higher spending on medical care
more broadly and not just on long-term care services. The
fact that this pattern is not observed suggests that the
estimates we obtain may reflect differences in spending
attributable to dementia.
Second, the study relies on self-reported information on
OOP spending and utilization of care, and we have no way
of directly assessing the validity of these outcomes. How-
ever, studies [4] using data from the Medicare Current Ben-
eficiary Survey that include information from Medicare
claims records that are used to cross-check self-reported
OOP spending also show that OOP spending is higher
among patients with chronic conditions. Although the lack
of Medicare coverage for long-term care makes these
findings not fully comparable with those reported here, it
is important to note that the HRS questions are designed to
minimize underreporting bias in OOP spending measures
[31], and other research [32] supports the internal consis-
tency of the HRS OOP spending measures. Similarly, the
validity of self-reported data on dental care utilization has
been found to be high [37], and several studies have found
that self-reported information on prescription drug use cor-
responds well with information from claims data [38–40].
However, we acknowledge that the OOP spending
measures we use likely contain some misreporting, and
this represents an important limitation of the study. In partic-
ular, this misreporting could result in bias for our estimates
of the association between dementia and spending if the
severity and direction of misreporting differ by dementia
status. However, we see no obvious reason why the quality
of the spending information would differ between individ-
uals with and without dementia to such a degree that it would
fully account for the very large OOP spending burden of
dementia we find.
This claim finds further support in auxiliary analyses
(available on request) conducted with Medicare claims
data linked to the ADAMS–HRS data. The results from these
analyses indicate that dementia is associated with large
increases in spending on nursing home care but is not
associated with increases in spending on other types of
A. Delavande et al. / Alzheimer’s & Dementia 9 (2013) 19–2926care. Medicare only covers a small subset of total nursing
home stays (specifically those for postacute care); therefore,
the magnitude of the association between dementia and
nursing home spending in the Medicare claims data is not
directly comparable with the association between dementia
and OOP spending (which is driven precisely by those nurs-
ing home stays not covered by Medicare). Nonetheless, in
both the claims records and in the self-reported OOP spend-
ing data, we find that dementia is significantly related to
expenditures on nursing home care but not on other types
of care. This similarity provides reassurance that differential
misreporting is unlikely to be the chief explanation for our
main findings.
Third, the sample used in this article excludes ADAMS
participants who did not complete the HRS interview after
ADAMS. Consequently, our sample has better cognitive
health, as evidenced by the lower dementia prevalence
(11.4%) compared with the entire ADAMS sample
(13.9%). Because our sample is healthier relative to the
population, some of the more costly cases of dementia
may be excluded. Thus, our estimates may understate the
OOP spending burden of dementia.
We also explored using spending and utilization from the
HRS wave before ADAMS rather than from the HRS wave
after ADAMS. Many of the findings were similar to those
reported previously, including significantly higher levels of
spending on nursing home and hospital care, much higher
incidence of very large OOP expenditures among those
with dementia, and no significant differences in the utiliza-
tion of dental care or prescription drugs. However, we found
two differences. Among the respondents interviewed in both
waves (N 5 458), spending among those diagnosed with
dementia in ADAMS was substantially lower in the HRS
wave preceding ADAMS than in the wave after it ($6009
compared with $10,039, P 5 .09). This suggests that some
of these individuals had not yet progressed to dementia
status in the previous HRS wave. Second, when we adjusted
for covariates, total OOP spending did not differ signifi-
cantly across dementia diagnosis categories in the previous
HRS wave. Qualitatively this is to be expected because of
classification error—some individuals classified as de-
mented in ADAMS would not have yet been demented in
the previous HRS waves. Such misclassification at the
time of the cost measurement (in the previous HRS wave)
would attenuate the relationship between dementia and
cost. We interpret these differences as support for using
cost measurement from the HRS wave after the ADAMS
assessment rather than from the previous HRS wave.
A fourth limitation concerns the generalizability of the
finding that dementia is not associated with reductions in
other care and health goods that are frequently paid for
OOP. One reason is that the costs of prescription medications
may be included in nursing home fees. In auxiliary analyses,
we find mixed support for this hypothesis; nursing home
residence is associated with a reduction in the likelihood of
reporting positive OOP spending on prescription drugs(P , .01), whereas no statistically significant relationship
was found between OOP spending for nursing homes and
for prescription medications. A second reason why these
results may not be generalizable is that physicians typically
reduce the intensity of treatment for other conditions as
a patient’s dementia progresses, therebymitigating the trade-
off between paying for care related to dementia and other
forms of medical care. In contrast, such a tradeoff might
be more pressing for patients experiencing high OOP
expenditures for treatment of different chronic conditions.
Finally, this analysis does not address other ways in
which high OOP spending could diminish the wellbeing of
patients with dementia. For instance, large OOP expendi-
tures could make it difficult for individuals to afford other
necessities such as nutritious food, clothing, and heat or
air conditioning. However, the OOP expenses observed in
our data appear to be for nursing home care, which is where
these needs are presumably met. A related point is that the
OOP spending burden may be borne, at least to some extent,
by the children of individuals with dementia in the form of
smaller or nonexistent bequests. Future research should
determine who bears the burden of the large OOP expenses
associated with dementia.
Acknowledgments
Financial support from the National Institute on Aging
under grant R01AG030155 is gratefully acknowledged.
The HRS and ADAMS are funded by the National Institute
on Aging (U01 AG009740), and administered by the Insti-
tute for Social Research at the University of Michigan.
References
[1] Altman B, Cooper PF, Cunningham PJ. The case of disability in the
family: impact on health care utilization and expenditures for nondis-
abled members. Milbank Q 1999;77:39–75.
[2] Federman AD, Adams AS, Ross-Degman D. Supplemental insurance
and use of effective cardiovascular drugs among elderly Medicare
beneficiaries with coronary heart disease. J Am Med Assoc 2001;
276:1473–9.
[3] Cubanski J, DamicoA, Neuman T. Health care on a budget: an analysis
of spending by Medicare households. The Henry J. Kaiser Family
Foundation, 2009. Cited January 6, 2011. Available at: http://www.
kff.org/medicare/upload/7859.pdf.
[4] GrossD,BranganN.Out of pocket spendingonhealth care byMedicare
beneficiaries age 65 and older: 1999 projections. Washington, D.C:
Public Policy Institute Issue Brief, American Association of Retired
Persons; 1999. p. 1–14.
[5] Himmelstein DU, Warren E, Thorne D, Woolhandler S. Illness and
injury as contributors to bankruptcy. Health Aff 2006;25:74–83.
[6] Neuman T, Cubanski J, Damico A. Revisiting “skin in the game”
among Medicare beneficiaries. an updated analysis of the increasing
financial burden of health care spending from 1997 to 2005, 2009.
Cited January 6, 2011. Available at: http://www.kff.org/medicare/
upload/7860.pdf.
[7] Schneeweiss S, Patrick A, Pedan A, Varasteh L, Levin R, Liu N,
Shrank W. The effect of Medicare part D coverage on drug use and
cost sharing among seniors without prior drug benefits. Health Aff
2009;28:w305–16.
A. Delavande et al. / Alzheimer’s & Dementia 9 (2013) 19–29 27[8] Cassel CK, Besdine RW, Siegel LC. Restructuring Medicare for the
next century: what will beneficiaries really need? Health Aff 1999;
18:118–31.
[9] Smith GE, O’Brien PC, Ivnik RJ. Prospective analysis of risk factors
for nursing home placement of dementia patients. Neurology 2001;
57:1467–73.
[10] Yaffe K, Fox P, Newcomer R. Patient and caregiver characteristics and
nursing home placement in patients with dementia. J Am Med Assoc
2002;287:2090–7.
[11] Newcomer R, Clay R, Luxenberg J. Misclassification and selection
bias when identifying Alzheimer’s disease solely from Medicare
claims records. J Am Geriatr Soc 1999;47:215–21.
[12] O’Brien E. Medicare and long-term care. Georgetown University
Long-Term Care Financing Project; 2007. Cited January 6, 2011.
Available at: http://ltc.georgetown.edu/pdfs/medicare0207.pdf.
[13] Gardner L, Gilleskie D. The effects of state Medicaid policies on the
dynamic savings patterns of the elderly. Cambridge, MA: NBER;
2006. NBERWorking Paper #12208.
[14] Norton E. Elderly assets, Medicaid policy, and spend-down in nursing
homes. Rev Income Wealth 2005;41:309–29.
[15] Spence D, Weiner J. Estimating the extent of Medicaid spend-down in
nursing homes. J Health Polit Policy Law 1990;15:607–26.
[16] Brummel-Smith K, Weiner M, Powe N. Alzheimer’s disease under
managed care: implications fromMedicare utilization and expenditure
patterns. J Am Geriatr Soc 1998;46:762–71.
[17] Gutterman E, Markowitz A, Lewis B. Cost of Alzheimer’s disease and
related dementia in managed-Medicare. J Am Geriatr Soc 1999;
47:1065–73.
[18] Hill J, Futterman R, Duttagupta S. Alzheimer’s disease and related
dementias increase costs of comorbidities in managed Medicare.
Neurology 2002;58:62–70.
[19] Langa KM, Larson E, Wallace RB, Fendrick AM, Foster NL,
Kabeto MU, Weir DR, Willis RJ, Herzog AR. Out of pocket health
care expenditures among older Americans with dementia. Alzheimers
Dis Assoc Disord 2004;18:90–8.
[20] McCormick WC, Hardy J, Kukull WA, Bowen JD, Teri L, Zitzer S,
Larson E. Healthcare utilization in costs in managed care patients
with Alzheimer’s disease during the last few years of life. JAmGeriatr
Soc 2001;49:1156–60.
[21] Walsh G, Wu B, Mitchell J, Berkman L. Cognitive function and acute
care utilization. J Gerontol Br 2003;58:S38–49.
[22] Andersen CK, Sogaard J, Hansen E, Kragh-Sorensen A, Hastrup L.
The cost of dementia in Denmark: the odense study. Dement Geriatr
Cogn Disord 1997;10:295–304.
[23] Di Carlo A, Baldereschi M, Amaducci L, Maggi S, Grigoletto F,
Scarlato G. Cognitive impairment without dementia in older people:
prevalence, vascular risk factors, impact on disability: the Italian
longitudinal study on aging. J Am Geriatr Soc 2000;48:775–82.
[24] Callahan CM, Hendrie HC, Tierney WM. Documentation and evalua-
tion of cognitive impairment in elderly primary care patients. Ann
Intern Med 1995;122:422–9.[25] Juster F, Suzman R. An overview of the health and retirement study.
J Hum Resour 1995;30:S7–56.
[26] Heeringa SG, Fisher G, Hurd M, Langa KM, Ofstedal MB, Plassman
BL. Aging, demographics and memory study (ADAMS). Sample
design, weighting and analysis for ADAMS. University of Michigan;
2009. Cited January 6, 2011. Available at: http://hrsonline.isr.umich.
edu/sitedocs/userg/ADAMSSampleWeights_Jun2009.pdf.
[27] Langa KM, Plassman BL, Wallace RB, Herzog AR, Heeringa S. The
aging, demographics and memory study: study design and methods.
Neuroepidemiology 2005;25:181–91.
[28] Cohen S, Carlson B. A comparison of household and medical
provider reported expenditures in the 1987 NMES. J Off Stat
1994;10:3–29.
[29] Bound J, Brown C, Mathiowetz N. Measurement error in survey data.
In: Heckman J, Leamer E, eds. Handbook of econometrics, Vol. 5.
North-Holland: Elsevier Science; 2001. p. 3705–842.
[30] Cao H. Impute: a SAS application system for missing value imputa-
tions. Ann Arbor, MI: University of Michigan; 2009. Cited January
6, 2011. Available at: http://hrsonline.isr.umich.edu/sitedocs/userg/
dr-007.pdf.
[31] Hurd M, Rodgers W. The effects of bracketing and anchoring on
measurement in the health and retirement study. Ann Arbor, MI:
Institute for Social Research; 2008.
[32] Johnson RW, Crystal S. Uninsured status and out-of-pocket costs at
midlife. Health Serv Res 2000;35(5 Pt 1):911–32.
[33] SteinmanM, Sands L, Covinsky K. Self-restriction of medications due
to cost in seniors without prescription drug coverage. J Gen InternMed
2001;16:793–9.
[34] Heisler M, Choi H, Rosen A, Vijan S, Kabeto M, Langa K, Piette D.
Hospitalizations and deaths among adults with cardiovascular disease
who underuse medications because of cost: a longitudinal analysis.
Med Care 2010;48:87–94.
[35] Langa K, Chernew M, Kabeto MU, Herzog R, Ofstedal MB, Willis R,
Wallace R, Mucha L, Straus W, Fendrick M. National estimates of the
quantity and cost of informal caregiving for the elderly with dementia.
J Gen Intern Med 2001;16:770–8.
[36] U.S. Census Bureau. US Interim Projections 2000-2050. Available at:
http://www.census.gov/population/www/projections/usinterimproj/
usproj2000-2050.xls. Accessed December 8, 2010.
[37] Gilbert GH, Rose JS, Shelton BJ. A prospective study of the validity of
data on self-reported dental visits. Community Dent Oral Epidemiol
2002;30:352–62.
[38] Sjahid SI, van der Linden PD, Stricker BH. Agreement between the
pharmacy medication history and patient interview for cardiovascular
drugs: theRotterdamelderly study.Br JClinPharmacol 1998;45:591–5.
[39] Rost K, Roter D. Predictors of recall of medication regimens and
recommendations for lifestyle change in elderly patients. Gerontolo-
gist 1987;27:510–5.
[40] West SL, Savitz DA, Koch G, Strom BL, Guess HA, Hartzema A.
Recall accuracy for prescription medications: self-report compared
with database information. Am J Epidemiol 1995;142:1103–12.
Table A1
Regression coefficients for annual OOP spending levels







CIND 2302.21* (612.31) 721.06 (872.31) 689.26 (490.88) 891.89 (797.58)
Demented 5646.42* (1412.87) 4649.01** (1307.83) 649.74 (396.16) 347.68 (630.57)
Male 2462.41 (1289.07) 292.62 (747.73) 34.30 (270.83) 2789.33 (526.86)
Married 21063.19 (1071.96) 21105.86*** (499.46) 2140.46 (385.16) 183.13 (419.72)
One or no children 230.35 (857.12) 525.97 (867.52) 223.66 (245.49) 2532.66 (447.37)
Two children 200.69 (542.28) 637.81 (503.74) 2116.06 (242.06) 2321.06 (341.39)
White 901.23 (733.60) 308.00 (595.01) 696.56*** (332.94) 2103.32 (428.36)
Hispanic 935.66 (935.15) 1144.43 (639.40) 363.44 (232.74) 2572.21 (404.67)
Have long-term care insurance 2729.23 (656.90) 2785.10*** (374.54) 249.65 (462.05) 2193.79 (409.17)
Have supplemental private
insurance
247.24 (943.52) 152.72 (693.87) 683.34*** (315.63) 2588.81*** (256.64)
Covered by Medicaid 23553.12** (1083.01) 21992.41 (1018.89) 2892.35*** (335.12) 2668.35*** (265.80)
Less than high school 22291.15 (1365.45) 22305.23 (1465.64) 176.62 (419.55) 2162.55 (397.68)
High school graduate 59.61 (1397.64) 21484.68 (1119.40) 362.53 (334.27) 1181.76*** (567.60)
Months between ADAMS
and after HRS interview
20.61 (1.31) 0.11 (0.93) 20.64 (0.58) 20.09 (0.57)
Age 51.02 (138.92) 28.04 (138.41) 9.01 (27.11) 13.97 (74.71)
Age squared 20.02 (0.07) 20.01 (0.07) 20.01 (0.01) 20.01 (0.04)
Household income 0.02** (0.01) 20.00 (0.00) 0.01 (0.01) 0.02*** (0.01)
Stroke 1900.43 (1953.81) 2310.62 (1419.01) 2259.67 (315.24) 2150.53 (525.71)
Diabetes 449.41 (1232.16) 2751.70 (548.07) 581.18 (366.34) 619.93 (586.30)
Heart disease 2116.96*** (819.18) 1054.46 (810.37) 386.69 (240.16) 675.80 (362.78)
Hypertension 1789.41*** (725.94) 887.11 (791.48) 495.88 (261.60) 406.42 (341.71)
Lung disease 1498.68 (2004.37) 2280.00 (1941.78) 2364.79 (421.63) 2416.54 (608.94)
Cancer 339.16 (1249.56) 2202.57 (708.55) 288.79 (295.22) 630.51 (637.79)
Psychological condition 305.15 (696.28) 425.20 (685.58) 362.10 (301.28) 2482.15 (480.86)
Arthritis 2517.01 (552.76) 2522.89 (567.67) 45.85 (275.09) 239.97 (289.62)
Proxy interview 5368.60 (2723.88) 3617.66 (2215.17) 2165.19 (477.51) 1916.13 (2119.42)
Intercept 228,156.65 (67,474.10) 215,874.22 (67,218.48) 23998.90 (13,822.79) 28283.53 (36,594.38)
Number of observations 743 743 743 743
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Table A2
Logistic regression coefficients for health care utilization and incidence of large OOP expenditures
Dependent variable Visited dentist
Did not take prescription
medications owing to cost
Annual OOP spending
greater than $5000
CIND 20.24 (0.27) 20.25 (0.59) 0.92* (0.35)
Demented 20.63 (0.44) 0.29 (0.60) 1.73** (0.49)
Male 20.37 (0.25) 21.27 (0.79) 0.32 (0.35)
Married 0.64* (0.29) 0.56 (0.54) 20.72 (0.40)
One or no children 0.48 (0.24) 0.08 (0.59) 0.39 (0.40)
Two children 0.40 (0.23) 20.65 (0.66) 20.24 (0.23)
White 0.27 (0.37) 20.81 (0.80) 0.78 (0.60)
Hispanic 20.86 (0.63) 21.80* (0.73) 0.27 (0.81)
Have long-term care insurance 0.74 (0.45) 0.97 (0.80) 20.67 (0.39)
Have supplemental private insurance 0.27 (0.25) 0.80 (0.53) 0.44 (0.36)
Covered by Medicaid 20.43 (0.44) 21.25 (0.78) 20.65 (0.38)
Less than high school 21.24*** (0.31) 1.21* (0.58) 20.42 (0.43)
High school graduate 20.62 (0.32) 0.83 (0.87) 0.53 (0.33)
Months between ADAMS
and after HRS interview
0.00 (0.00) 20.00 (0.00) 0.00 (0.00)
Age 20.02 (0.27) 21.52** (0.52) 20.21 (0.40)
Age squared 0.00 (0.00) 0.01** (0.00) 0.00 (0.00)
Household income 0.01* (0.01) 0.01 (0.01) 0.01*** (0.00)
Stroke 0.01 (0.43) 20.01 (0.99) 20.07 (0.44)
Diabetes 0.36 (0.25) 0.15 (0.55) 0.65 (0.53)
Heart disease 0.26 (0.24) 0.12 (0.42) 0.55* (0.26)
Hypertension 20.01 (0.20) 0.19 (0.49) 0.98** (0.34)
Lung disease 20.25 (0.43) 0.66 (0.88) 20.15 (0.31)
Cancer 20.29 (0.31) 0.74 (0.53) 20.35 (0.34)
Psychological condition 20.40 (0.32) 2.02*** (0.52) 0.03 (0.35)
Arthritis 20.01 (0.36) 0.56 (0.78) 0.25 (0.32)
Proxy interview 0.27 (0.36) 22.26* (0.92) 0.00 (0.42)
Intercept 0.96 (11.10) 58.49** (20.73) 4.39 (16.13)
Number of observations 739 740 743
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